{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T22:09:52Z","timestamp":1777154992350,"version":"3.51.4"},"reference-count":55,"publisher":"MDPI AG","issue":"17","license":[{"start":{"date-parts":[[2023,8,30]],"date-time":"2023-08-30T00:00:00Z","timestamp":1693353600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran","award":["4-43006704"],"award-info":[{"award-number":["4-43006704"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diagnostics"],"abstract":"<jats:p>Background: We aimed to investigate the association between kidney stones and polycystic ovarian syndrome (PCOS). Materials and methods: In a cross-sectional study, data from the Tehran Lipid and Glucose Study (TLGS) were used to investigate the risk of kidney stones in women with Polycystic Ovary Syndrome (PCOS). Four distinct phenotypes of PCOS, as defined by the Rotterdam criteria, were examined in a sample of 520 women and compared to a control group of 1638 eumenorrheic non-hirsute healthy women. Univariate and multivariable logistic regression models were employed for analysis. The four PCOS phenotypes were classified as follows: Phenotype A, characterized by the presence of all three PCOS features (anovulation (OA), hyperandrogenism (HA), and polycystic ovarian morphology on ultrasound (PCOM)); Phenotype B, characterized by the presence of anovulation and hyperandrogenism; Phenotype C, characterized by the presence of hyperandrogenism and polycystic ovarian morphology on ultrasound; and Phenotype D, characterized by the presence of anovulation and polycystic ovarian morphology on ultrasound. Results: The prevalence of a history of kidney stones was found to be significantly higher in women with Polycystic Ovary Syndrome (PCOS) compared to healthy controls (12.5% vs. 7.7%, p = 0.001). This increased prevalence was observed across all PCOS phenotypes (p &lt; 0.001). After adjusting for potential risk factors, including age, family history of kidney stones, waist-to-height ratio, total cholesterol, and low-density lipoprotein, the odds ratio for kidney stones in women with PCOS was found to be 1.59 [95% CI: 1.12\u20132.25, p = 0.01], indicating a 59% increase in risk compared to healthy women. Women with PCOS Phenotype A [OR: 1.97, 95% CI: 1.09\u20133.55, p = 0.02] and Phenotype D [OR: 3.03, 95% CI: 1.24\u20137.41, p = 0.01] were found to be at a higher risk for kidney stones. Conclusion: Women with Polycystic Ovary Syndrome (PCOS), particularly those exhibiting menstrual irregularities and polycystic ovarian morphology on ultrasound (PCOM), have been found to be two to three times more likely to develop kidney stones. This increased prevalence should be taken into consideration when providing preventive care and counseling to these individuals.<\/jats:p>","DOI":"10.3390\/diagnostics13172814","type":"journal-article","created":{"date-parts":[[2023,8,30]],"date-time":"2023-08-30T10:09:49Z","timestamp":1693390189000},"page":"2814","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["The Hidden Link between Polycystic Ovary Syndrome and Kidney Stones: Finding from the Tehran Lipid and Glucose Study (TLGS)"],"prefix":"10.3390","volume":"13","author":[{"given":"Marzieh","family":"Rostami Dovom","sequence":"first","affiliation":[{"name":"Reproductive Endocrinology Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran 1985717413, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maryam","family":"Rahmati","sequence":"additional","affiliation":[{"name":"Reproductive Endocrinology Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran 1985717413, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saber","family":"Amanollahi Soudmand","sequence":"additional","affiliation":[{"name":"Urology Department, Labafinejad Hospital, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran 1985717443, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1074-1518","authenticated-orcid":false,"given":"Pardis","family":"Ziaeefar","sequence":"additional","affiliation":[{"name":"School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran 1985717443, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fereidoun","family":"Azizi","sequence":"additional","affiliation":[{"name":"Endocrine Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran 1985717413, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fahimeh","family":"Ramezani Tehrani","sequence":"additional","affiliation":[{"name":"Reproductive Endocrinology Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran 1985717413, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,8,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1097\/AOG.0000000000002698","article-title":"Polycystic ovary syndrome","volume":"132","author":"Azziz","year":"2018","journal-title":"Obstet. Gynecol."},{"key":"ref_2","first-page":"407","article-title":"Polycystic ovary syndrome","volume":"53","author":"Meier","year":"2018","journal-title":"Nurs. Clin."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"R85","DOI":"10.1530\/EJE-20-1093","article-title":"Management of endocrine disease: Gonadal dysfunction in congenital adrenal hyperplasia","volume":"184","author":"Stikkelbroeck","year":"2021","journal-title":"Eur. J. Endocrinol."},{"key":"ref_4","first-page":"3347","article-title":"Polycystic ovary syndrome and the neuroendocrine consequences of androgen excess","volume":"12","author":"Silva","year":"2011","journal-title":"Compr. Physiol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/j.fertnstert.2014.01.003","article-title":"Prevalence of androgenic alopecia in patients with polycystic ovary syndrome and characterization of associated clinical and biochemical features","volume":"101","author":"Quinn","year":"2014","journal-title":"Fertil. Steril."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1056\/NEJMcp033496","article-title":"Hirsutism","volume":"353","author":"Rosenfield","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1210\/js.2019-00078","article-title":"Polycystic ovary syndrome: Pathophysiology, presentation, and treatment with emphasis on adolescent girls","volume":"3","author":"Witchel","year":"2019","journal-title":"J. Endocr. Soc."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1210\/jc.2003-031122","article-title":"Androgen excess in women: Experience with over 1000 consecutive patients","volume":"89","author":"Azziz","year":"2004","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1016\/j.fertnstert.2008.12.138","article-title":"Prevalence of hyperandrogenemia in the polycystic ovary syndrome diagnosed by the National Institutes of Health 1990 criteria","volume":"93","author":"Huang","year":"2010","journal-title":"Fertil. Steril."},{"key":"ref_10","first-page":"CD007506","article-title":"Lifestyle changes in women with polycystic ovary syndrome","volume":"3","author":"Moran","year":"2019","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"3679493","DOI":"10.1155\/2019\/3679493","article-title":"Nephrolithiasis and polycystic ovary syndrome: A case-control study evaluating testosterone and urinary stone metabolic panels","volume":"2019","author":"Fedrigon","year":"2019","journal-title":"Adv. Urol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s00240-013-0564-9","article-title":"Is polycystic ovarian syndrome a risk factor for urolithiasis?","volume":"41","author":"Kaygusuz","year":"2013","journal-title":"Urolithiasis"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1007\/s00345-017-2008-6","article-title":"Epidemiology of stone disease across the world","volume":"35","author":"Sorokin","year":"2017","journal-title":"World J. Urol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.ucl.2007.04.003","article-title":"Epidemiology of stone disease","volume":"34","author":"Curhan","year":"2007","journal-title":"Urol. Clin. N. Am."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1007\/s00240-005-0511-5","article-title":"Influence of estrus status on urinary chemical parameters related to urolithiasis","volume":"33","author":"Kato","year":"2005","journal-title":"Urol. Res."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Naghii, M.R., Babaei, M., and Hedayati, M. (2014). Androgens involvement in the pathogenesis of renal stones formation. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0093790"},{"key":"ref_17","first-page":"15","article-title":"Epidemiological risk factors in calcium stone disease","volume":"53","author":"Robertson","year":"1980","journal-title":"Scand. J. Urol. Nephrol. Suppl."},{"key":"ref_18","first-page":"181","article-title":"Renal lithiasis in review","volume":"1","author":"Finlayson","year":"1974","journal-title":"Urol. Clin. N. Am."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.urology.2009.09.094","article-title":"Effect of sex hormones on crystal formation in a stone-forming rat model","volume":"75","author":"Yoshioka","year":"2010","journal-title":"Urology"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1007\/s00345-019-02726-6","article-title":"Testosterone replacement therapy is associated with an increased risk of urolithiasis","volume":"37","author":"McClintock","year":"2019","journal-title":"World J. Urol."},{"key":"ref_21","first-page":"e84777","article-title":"Review of rationale, design, and initial findings: Tehran Lipid and Glucose Study","volume":"16","author":"Azizi","year":"2018","journal-title":"Int. J. Endocrinol. Metab."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1210\/jcem-21-11-1440","article-title":"Clinical assessment of body hair growth in women","volume":"21","author":"Ferriman","year":"1961","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_23","first-page":"1","article-title":"Epidemiology, diagnosis, and management of polycystic ovary syndrome","volume":"6","author":"Sirmans","year":"2014","journal-title":"Clin. Epidemiol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00240-010-0276-3","article-title":"An assessment of parathyroid hormone, calcitonin, 1, 25 (OH) 2 vitamin D3, estradiol and testosterone in men with active calcium stone disease and evaluation of its biochemical risk factors","volume":"39","author":"Shakhssalim","year":"2011","journal-title":"Urol. Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.1001\/jama.1982.03320430047030","article-title":"Evaluating the yield of medical tests","volume":"247","author":"Harrell","year":"1982","journal-title":"JAMA"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1097\/01.CCM.0000275267.64078.B0","article-title":"Assessing the calibration of mortality benchmarks in critical care: The Hosmer-Lemeshow test revisited","volume":"35","author":"Kramer","year":"2007","journal-title":"Crit. Care Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1089\/end.1999.13.629","article-title":"Epidemiologic evidence for the role of oxalate in idiopathic nephrolithiasis","volume":"13","author":"Curhan","year":"1999","journal-title":"J. Endourol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"37","DOI":"10.3834\/uij.1944-5784.2013.06.11","article-title":"The Role of Serum Testosterone as a Lithogenic Factor and Its Correlation with Stone and Urine Composition Amongst Male Stone Formers","volume":"6","author":"Nath","year":"2013","journal-title":"UroToday Int. J."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Zhao, Z., Mai, Z., Ou, L., Duan, X., and Zeng, G. (2013). Serum estradiol and testosterone levels in kidney stones disease with and without calcium oxalate components in naturally postmenopausal women. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0075513"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/S0022-5347(01)65914-7","article-title":"Testosterone enhances whereas estrogen inhibits calcium oxalate stone formation in ethylene glycol treated rats","volume":"156","author":"Lee","year":"1996","journal-title":"J. Urol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"241","DOI":"10.4103\/2229-516X.192593","article-title":"Possible role of elevated serum testosterone in pathogenesis of renal stone formation","volume":"6","author":"Gupta","year":"2016","journal-title":"Int. J. Appl. Basic Med. Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1089\/end.2015.0255","article-title":"Sex steroid hormone levels may not explain gender differences in development of nephrolithiasis","volume":"29","author":"Knoedler","year":"2015","journal-title":"J. Endourol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"83","DOI":"10.4081\/aiua.2015.1.83","article-title":"Urolithiasis is associated with low serum testosterone levels in men","volume":"87","author":"Otunctemur","year":"2015","journal-title":"Arch. Ital. Urol. Androl."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1089\/end.2010.0113","article-title":"Serum testosterone may be associated with calcium oxalate urolithogenesis","volume":"24","author":"Watson","year":"2010","journal-title":"J. Endourol."},{"key":"ref_35","first-page":"818010","article-title":"The role of androgen hormones in early follicular development","volume":"2014","author":"Bernuci","year":"2014","journal-title":"Int. Sch. Res. Not."},{"key":"ref_36","first-page":"174","article-title":"The Role of microRNAs in Ovarian Granulosa Cells in Health and Disease","volume":"10","author":"Tu","year":"2019","journal-title":"Fertil. Preserv. Asia"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Vishnoi, A., and Rani, S. (2017). MiRNA biogenesis and regulation of diseases: An overview. MicroRNA Profiling, 1\u201310.","DOI":"10.1007\/978-1-4939-6524-3_1"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.gene.2019.04.082","article-title":"The role of MiRNA in polycystic ovary syndrome (PCOS)","volume":"706","author":"Chen","year":"2019","journal-title":"Gene"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Ruiz-Manriquez, L.M., Pacheco, S.J.L., Medina-Gomez, D., Uriostegui-Pena, A.G., Estrada-Meza, C., Bandyopadhyay, A., Pathak, S., Banerjee, A., Chakraborty, S., and Srivastava, A. (2022). A Brief Review on the Regulatory Roles of MicroRNAs in Cystic Diseases and Their Use as Potential Biomarkers. Genes, 13.","DOI":"10.3390\/genes13020191"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Wang, B., Wu, B., Liu, J., Yao, W., Xia, D., Li, L., Chen, Z., Ye, Z., and Yu, X. (2014). Analysis of altered microRNA expression profiles in proximal renal tubular cells in response to calcium oxalate monohydrate crystal adhesion: Implications for kidney stone disease. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0101306"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1177\/1933719116673197","article-title":"MicroRNA-145 negatively regulates cell proliferation through targeting IRS1 in isolated ovarian granulosa cells from patients with polycystic ovary syndrome","volume":"24","author":"Cai","year":"2017","journal-title":"Reprod. Sci."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.mce.2015.01.030","article-title":"Characterization of microRNA profile in human cumulus granulosa cells: Identification of microRNAs that regulate Notch signaling and are associated with PCOS","volume":"404","author":"Xu","year":"2015","journal-title":"Mol. Cell. Endocrinol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"8306736","DOI":"10.1155\/2017\/8306736","article-title":"Integrative analysis of miRNA and mRNA expression profiles in calcium oxalate nephrolithiasis rat model","volume":"2017","author":"Lan","year":"2017","journal-title":"BioMed Res. Int."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Butler, A.E., Ramachandran, V., Sathyapalan, T., David, R., Gooderham, N.J., Benurwar, M., Dargham, S.R., Hayat, S., Najafi-Shoushtari, S.H., and Atkin, S.L. (2020). microRNA Expression in Women With and Without Polycystic Ovarian Syndrome Matched for Body Mass Index. Front. Endocrinol., 11.","DOI":"10.3389\/fendo.2020.00515"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.7754\/Clin.Lab.2015.150122","article-title":"Ciculating miRNA-21 as a biomarker predicts polycystic ovary syndrome (PCOS) in patients","volume":"61","author":"Jiang","year":"2015","journal-title":"Clin. Lab."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s13048-019-0513-5","article-title":"Association of miRNA\u2212 320 expression level and its target gene endothelin-1 with the susceptibility and clinical features of polycystic ovary syndrome","volume":"12","author":"Rashad","year":"2019","journal-title":"J. Ovarian Res."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Song, D.K., Sung, Y.-A., and Lee, H. (2016). The role of serum microRNA-6767-5p as a biomarker for the diagnosis of polycystic ovary syndrome. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0163756"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"E2754","DOI":"10.1210\/jc.2013-4435","article-title":"The expression of the miR-25\/93\/106b family of micro-RNAs in the adipose tissue of women with polycystic ovary syndrome","volume":"99","author":"Wu","year":"2014","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Chen, W., and Pang, Y. (2021). Metabolic Syndrome and PCOS: Pathogenesis and the Role of Metabolites. Metabolites, 11.","DOI":"10.3390\/metabo11120869"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1055\/s-0032-1328878","article-title":"Obesity and PCOS: Implications for diagnosis and treatment","volume":"30","author":"Legro","year":"2012","journal-title":"Semin. Reprod Med."},{"key":"ref_51","first-page":"393","article-title":"Obesity and kidney stone disease: A systematic review","volume":"70","author":"Carbone","year":"2018","journal-title":"Minerva Urol. Nefrol. = Ital. J. Urol. Nephrol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.molmed.2006.05.006","article-title":"Molecular mechanisms of insulin resistance in polycystic ovary syndrome","volume":"12","author":"Papavassiliou","year":"2006","journal-title":"Trends Mol. Med."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.2105\/AJPH.2016.303319","article-title":"Insights Into Nephrolithiasis From the Nurses\u2019 Health Studies","volume":"106","author":"Prochaska","year":"2016","journal-title":"Am. J. Public Health"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1161\/HYPERTENSIONAHA.106.083972","article-title":"Relationship between androgen levels and blood pressure in young women with polycystic ovary syndrome","volume":"49","author":"Chen","year":"2007","journal-title":"Hypertension"},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Mirabelli, M., Chiefari, E., Arcidiacono, B., Corigliano, D.M., Brunetti, F.S., Maggisano, V., Russo, D., Foti, D.P., and Brunetti, A. (2020). Mediterranean Diet Nutrients to Turn the Tide against Insulin Resistance and Related Diseases. Nutrients, 12.","DOI":"10.3390\/nu12041066"}],"container-title":["Diagnostics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4418\/13\/17\/2814\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:43:19Z","timestamp":1760128999000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4418\/13\/17\/2814"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,30]]},"references-count":55,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2023,9]]}},"alternative-id":["diagnostics13172814"],"URL":"https:\/\/doi.org\/10.3390\/diagnostics13172814","relation":{},"ISSN":["2075-4418"],"issn-type":[{"value":"2075-4418","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,30]]}}}